Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Cullinan Therapeutics (CGEM) Shares Outstanding (Diluted Average) (2021 - 2023)

Cullinan Therapeutics (CGEM) has 3 years of Shares Outstanding (Diluted Average) data on record, last reported at $42.7 million in Q3 2023.

  • For Q3 2023, Shares Outstanding (Diluted Average) fell 8.26% year-over-year to $42.7 million; the TTM value through Sep 2023 reached $42.7 million, down 8.26%, while the annual FY2022 figure was $46.6 million, 8.27% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $42.7 million in Q3 2023 per CGEM's latest filing, up from $40.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $46.6 million in Q4 2022 and bottomed at $40.0 million in Q2 2023.
  • Average Shares Outstanding (Diluted Average) over 3 years is $43.6 million, with a median of $43.2 million recorded in 2021.
  • Peak YoY movement for Shares Outstanding (Diluted Average): grew 8.61% in 2022, then decreased 13.88% in 2023.
  • A 3-year view of Shares Outstanding (Diluted Average) shows it stood at $43.1 million in 2021, then grew by 8.27% to $46.6 million in 2022, then fell by 8.37% to $42.7 million in 2023.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $42.7 million in Q3 2023, $40.0 million in Q2 2023, and $40.7 million in Q1 2023.